ERIS2021-10-012022-03-31ERIS2022-03-31ERIS2021-10-012022-03-31RelatedPartyTransactionDomain1ERIS2021-09-30RelatedPartyTransactionDomain1ERIS2022-03-31RelatedPartyTransactionDomain1ERIS2021-10-012022-03-31RelatedPartyTransactionDomain2ERIS2021-09-30RelatedPartyTransactionDomain2ERIS2022-03-31RelatedPartyTransactionDomain2ERIS2021-10-012022-03-31RelatedPartyTransactionDomain3ERIS2021-09-30RelatedPartyTransactionDomain3ERIS2022-03-31RelatedPartyTransactionDomain3ERIS2021-10-012022-03-31RelatedPartyTransactionDomain4ERIS2021-09-30RelatedPartyTransactionDomain4ERIS2022-03-31RelatedPartyTransactionDomain4ERIS2021-10-012022-03-31RelatedPartyTransactionDomain5ERIS2021-09-30RelatedPartyTransactionDomain5ERIS2022-03-31RelatedPartyTransactionDomain5ERIS2021-10-012022-03-31RelatedPartyTransactionDomain6ERIS2021-09-30RelatedPartyTransactionDomain6ERIS2022-03-31RelatedPartyTransactionDomain6ERIS2021-10-012022-03-31RelatedPartyTransactionDomain7ERIS2021-09-30RelatedPartyTransactionDomain7ERIS2022-03-31RelatedPartyTransactionDomain7ERIS2021-10-012022-03-31RelatedPartyTransactionDomain8ERIS2021-09-30RelatedPartyTransactionDomain8ERIS2022-03-31RelatedPartyTransactionDomain8ERIS2021-10-012022-03-31RelatedPartyTransactionDomain9ERIS2021-09-30RelatedPartyTransactionDomain9ERIS2022-03-31RelatedPartyTransactionDomain9ERIS2021-10-012022-03-31RelatedPartyTransactionDomain10ERIS2021-09-30RelatedPartyTransactionDomain10ERIS2022-03-31RelatedPartyTransactionDomain10ERIS2021-10-012022-03-31RelatedPartyTransactionDomain11ERIS2021-09-30RelatedPartyTransactionDomain11ERIS2022-03-31RelatedPartyTransactionDomain11ERIS2021-10-012022-03-31RelatedPartyTransactionDomain12ERIS2021-09-30RelatedPartyTransactionDomain12ERIS2022-03-31RelatedPartyTransactionDomain12ERIS2021-10-012022-03-31RelatedPartyTransactionDomain13ERIS2021-09-30RelatedPartyTransactionDomain13ERIS2022-03-31RelatedPartyTransactionDomain13ERIS2021-10-012022-03-31RelatedPartyTransactionDomain14ERIS2021-09-30RelatedPartyTransactionDomain14ERIS2022-03-31RelatedPartyTransactionDomain14ERIS2021-10-012022-03-31RelatedPartyTransactionDomain15ERIS2021-09-30RelatedPartyTransactionDomain15ERIS2022-03-31RelatedPartyTransactionDomain15ERIS2021-10-012022-03-31RelatedPartyTransactionDomain16ERIS2021-09-30RelatedPartyTransactionDomain16ERIS2022-03-31RelatedPartyTransactionDomain16ERIS2021-10-012022-03-31RelatedPartyTransactionDomain17ERIS2021-09-30RelatedPartyTransactionDomain17ERIS2022-03-31RelatedPartyTransactionDomain17ERIS2021-10-012022-03-31RelatedPartyTransactionDomain18ERIS2021-09-30RelatedPartyTransactionDomain18ERIS2022-03-31RelatedPartyTransactionDomain18ERIS2021-10-012022-03-31RelatedPartyTransactionDomain19ERIS2021-09-30RelatedPartyTransactionDomain19ERIS2022-03-31RelatedPartyTransactionDomain19ERIS2021-10-012022-03-31RelatedPartyTransactionDomain20ERIS2021-09-30RelatedPartyTransactionDomain20ERIS2022-03-31RelatedPartyTransactionDomain20ERIS2021-10-012022-03-31RelatedPartyTransactionDomain21ERIS2021-09-30RelatedPartyTransactionDomain21ERIS2022-03-31RelatedPartyTransactionDomain21ERIS2021-10-012022-03-31RelatedPartyTransactionDomain22ERIS2021-09-30RelatedPartyTransactionDomain22ERIS2022-03-31RelatedPartyTransactionDomain22ERIS2021-10-012022-03-31RelatedPartyTransactionDomain23ERIS2021-09-30RelatedPartyTransactionDomain23ERIS2022-03-31RelatedPartyTransactionDomain23ERIS2021-10-012022-03-31RelatedPartyTransactionDomain24ERIS2021-09-30RelatedPartyTransactionDomain24ERIS2022-03-31RelatedPartyTransactionDomain24ERIS2021-10-012022-03-31RelatedPartyTransactionDomain25ERIS2021-09-30RelatedPartyTransactionDomain25ERIS2022-03-31RelatedPartyTransactionDomain25ERIS2021-10-012022-03-31RelatedPartyTransactionDomain26ERIS2021-09-30RelatedPartyTransactionDomain26ERIS2022-03-31RelatedPartyTransactionDomain26ERIS2021-10-012022-03-31RelatedPartyTransactionDomain27ERIS2021-09-30RelatedPartyTransactionDomain27ERIS2022-03-31RelatedPartyTransactionDomain27ERIS2021-10-012022-03-31RelatedPartyTransactionDomain28ERIS2021-09-30RelatedPartyTransactionDomain28ERIS2022-03-31RelatedPartyTransactionDomain28ERIS2021-10-012022-03-31RelatedPartyTransactionDomain29ERIS2021-09-30RelatedPartyTransactionDomain29ERIS2022-03-31RelatedPartyTransactionDomain29ERIS2021-10-012022-03-31RelatedPartyTransactionDomain30ERIS2021-09-30RelatedPartyTransactionDomain30ERIS2022-03-31RelatedPartyTransactionDomain30ERIS2021-10-012022-03-31RelatedPartyTransactionDomain31ERIS2021-09-30RelatedPartyTransactionDomain31ERIS2022-03-31RelatedPartyTransactionDomain31ERIS2021-10-012022-03-31RelatedPartyTransactionDomain32ERIS2021-09-30RelatedPartyTransactionDomain32ERIS2022-03-31RelatedPartyTransactionDomain32ERIS2021-10-012022-03-31RelatedPartyTransactionDomain33ERIS2021-09-30RelatedPartyTransactionDomain33ERIS2022-03-31RelatedPartyTransactionDomain33ERIS2021-10-012022-03-31RelatedPartyTransactionDomain34ERIS2021-09-30RelatedPartyTransactionDomain34ERIS2022-03-31RelatedPartyTransactionDomain34ERIS2021-10-012022-03-31RelatedPartyTransactionDomain35ERIS2021-09-30RelatedPartyTransactionDomain35ERIS2022-03-31RelatedPartyTransactionDomain35ERIS2021-10-012022-03-31RelatedPartyTransactionDomain36ERIS2021-09-30RelatedPartyTransactionDomain36ERIS2022-03-31RelatedPartyTransactionDomain36ERIS2021-10-012022-03-31RelatedPartyTransactionDomain37ERIS2021-09-30RelatedPartyTransactionDomain37ERIS2022-03-31RelatedPartyTransactionDomain37ERIS2021-10-012022-03-31RelatedPartyTransactionDomain38ERIS2021-09-30RelatedPartyTransactionDomain38ERIS2022-03-31RelatedPartyTransactionDomain38ERIS2021-10-012022-03-31RelatedPartyTransactionDomain39ERIS2021-09-30RelatedPartyTransactionDomain39ERIS2022-03-31RelatedPartyTransactionDomain39ERIS2021-10-012022-03-31RelatedPartyTransactionDomain40ERIS2021-09-30RelatedPartyTransactionDomain40ERIS2022-03-31RelatedPartyTransactionDomain40ERIS2021-10-012022-03-31RelatedPartyTransactionDomain41ERIS2021-09-30RelatedPartyTransactionDomain41ERIS2022-03-31RelatedPartyTransactionDomain41ERIS2021-10-012022-03-31RelatedPartyTransactionDomain42ERIS2021-09-30RelatedPartyTransactionDomain42ERIS2022-03-31RelatedPartyTransactionDomain42ERIS2021-10-012022-03-31RelatedPartyTransactionDomain43ERIS2021-09-30RelatedPartyTransactionDomain43ERIS2022-03-31RelatedPartyTransactionDomain43ERIS2021-10-012022-03-31RelatedPartyTransactionDomain44ERIS2021-09-30RelatedPartyTransactionDomain44ERIS2022-03-31RelatedPartyTransactionDomain44ERIS2021-10-012022-03-31RelatedPartyTransactionDomain45ERIS2021-09-30RelatedPartyTransactionDomain45ERIS2022-03-31RelatedPartyTransactionDomain45ERIS2021-10-012022-03-31RelatedPartyTransactionDomain46ERIS2021-09-30RelatedPartyTransactionDomain46ERIS2022-03-31RelatedPartyTransactionDomain46ERIS2021-10-012022-03-31RelatedPartyTransactionDomain47ERIS2021-09-30RelatedPartyTransactionDomain47ERIS2022-03-31RelatedPartyTransactionDomain47ERIS2021-10-012022-03-31RelatedPartyTransactionDomain48ERIS2021-09-30RelatedPartyTransactionDomain48ERIS2022-03-31RelatedPartyTransactionDomain48ERIS2021-10-012022-03-31RelatedPartyTransactionDomain49ERIS2021-09-30RelatedPartyTransactionDomain49ERIS2022-03-31RelatedPartyTransactionDomain49ERIS2021-10-012022-03-31RelatedPartyTransactionDomain50ERIS2021-09-30RelatedPartyTransactionDomain50ERIS2022-03-31RelatedPartyTransactionDomain50ERIS2021-10-012022-03-31RelatedPartyTransactionDomain51ERIS2021-09-30RelatedPartyTransactionDomain51ERIS2022-03-31RelatedPartyTransactionDomain51ERIS2021-10-012022-03-31RelatedPartyTransactionDomain52ERIS2021-09-30RelatedPartyTransactionDomain52ERIS2022-03-31RelatedPartyTransactionDomain52ERIS2021-10-012022-03-31RelatedPartyTransactionDomain53ERIS2021-09-30RelatedPartyTransactionDomain53ERIS2022-03-31RelatedPartyTransactionDomain53ERIS2021-10-012022-03-31RelatedPartyTransactionDomain54ERIS2021-09-30RelatedPartyTransactionDomain54ERIS2022-03-31RelatedPartyTransactionDomain54ERIS2021-10-012022-03-31RelatedPartyTransactionDomain55ERIS2021-09-30RelatedPartyTransactionDomain55ERIS2022-03-31RelatedPartyTransactionDomain55ERIS2021-10-012022-03-31RelatedPartyTransactionDomain56ERIS2021-09-30RelatedPartyTransactionDomain56ERIS2022-03-31RelatedPartyTransactionDomain56ERIS2021-10-012022-03-31RelatedPartyTransactionDomain57ERIS2021-09-30RelatedPartyTransactionDomain57ERIS2022-03-31RelatedPartyTransactionDomain57ERIS2021-10-012022-03-31RelatedPartyTransactionDomain58ERIS2021-09-30RelatedPartyTransactionDomain58ERIS2022-03-31RelatedPartyTransactionDomain58ERIS2021-10-012022-03-31RelatedPartyTransactionDomain59ERIS2021-09-30RelatedPartyTransactionDomain59ERIS2022-03-31RelatedPartyTransactionDomain59ERIS2021-10-012022-03-31RelatedPartyTransactionDomain60ERIS2021-09-30RelatedPartyTransactionDomain60ERIS2022-03-31RelatedPartyTransactionDomain60ERIS2021-10-012022-03-31RelatedPartyTransactionDomain61ERIS2021-09-30RelatedPartyTransactionDomain61ERIS2022-03-31RelatedPartyTransactionDomain61ERIS2021-10-012022-03-31RelatedPartyTransactionDomain62ERIS2021-09-30RelatedPartyTransactionDomain62ERIS2022-03-31RelatedPartyTransactionDomain62ERIS2021-10-012022-03-31RelatedPartyTransactionDomain63ERIS2021-09-30RelatedPartyTransactionDomain63ERIS2022-03-31RelatedPartyTransactionDomain63ERIS2021-10-012022-03-31RelatedPartyTransactionDomain64ERIS2021-09-30RelatedPartyTransactionDomain64ERIS2022-03-31RelatedPartyTransactionDomain64ERIS2021-10-012022-03-31RelatedPartyTransactionDomain65ERIS2021-09-30RelatedPartyTransactionDomain65ERIS2022-03-31RelatedPartyTransactionDomain65ERIS2021-10-012022-03-31RelatedPartyTransactionDomain66ERIS2021-09-30RelatedPartyTransactionDomain66ERIS2022-03-31RelatedPartyTransactionDomain66ERIS2021-10-012022-03-31RelatedPartyTransactionDomain67ERIS2021-09-30RelatedPartyTransactionDomain67ERIS2022-03-31RelatedPartyTransactionDomain67ERIS2021-10-012022-03-31RelatedPartyTransactionDomain68ERIS2021-09-30RelatedPartyTransactionDomain68ERIS2022-03-31RelatedPartyTransactionDomain68ERIS2021-10-012022-03-31RelatedPartyTransactionDomain69ERIS2021-09-30RelatedPartyTransactionDomain69ERIS2022-03-31RelatedPartyTransactionDomain69ERIS2021-10-012022-03-31RelatedPartyTransactionDomain70ERIS2021-09-30RelatedPartyTransactionDomain70ERIS2022-03-31RelatedPartyTransactionDomain70iso4217:INRxbrli:pureERIS LIFESCIENCES LIMITED540596ERISNA2021-04-012022-03-31Second half yearly2021-10-012022-03-31MillionstruetrueNANAfalsefalseEris Lifesciences LimitedAMIT BAKSHIManaging DirectorRemuneration50000000NA2439000025300002570000<DIV > <P class=MsoNormal style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 8pt; LINE-HEIGHT: 150%"><SPAN lang=EN-US style='FONT-FAMILY: "Arial",sans-serif; mso-ansi-language: EN-US'>The remuneration paid to the director is paid against the services provided by them to the company. The said remuneration is specifically approved by the shareholders in their AGM meeting held on 01<SUP>st</SUP> September, 2021 (which is a body superior to the Audit Committee). In any case, the financial results for the applicable quarter include the expenses pertaining to remuneration to this director and to this extent it gets approved by the Audit Committee while approving the financial results. </SPAN><SPAN style='FONT-FAMILY: "Arial",sans-serif'><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Eris Lifesciences LimitedINDERJEET SINGH NEGIDirectorRemuneration13000000NA6200000710000730000<DIV > <DIV> <P class=MsoNormal style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 8pt; LINE-HEIGHT: 150%"><SPAN lang=EN-US style='FONT-FAMILY: "Arial",sans-serif; mso-ansi-language: EN-US'>The remuneration paid to the director is paid against the services provided by them to the company. The said remuneration is specifically approved by the shareholders in their AGM meeting held on 01<SUP>st</SUP> September, 2021 (which is a body superior to the Audit Committee). In any case, the financial results for the applicable quarter include the expenses pertaining to remuneration to this director and to this extent it gets approved by the Audit Committee while approving the financial results. </SPAN><SPAN style='FONT-FAMILY: "Arial",sans-serif'><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Lifesciences LimitedKAUSHAL SHAHDirectorRemuneration7500000NA3500000430000460000<DIV > <P class=MsoNormal style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 8pt; LINE-HEIGHT: 150%"><SPAN lang=EN-US style='FONT-FAMILY: "Arial",sans-serif; mso-ansi-language: EN-US'>The remuneration paid to the director is paid against the services provided by them to the company. The said remuneration is specifically approved by the shareholders in their AGM meeting held on 01<SUP>st</SUP> September, 2020 (which is a body superior to the Audit Committee). In any case, the financial results for the applicable quarter include the expenses pertaining to remuneration to this director and to this extent it gets approved by the Audit Committee while approving the financial results. </SPAN><SPAN style='FONT-FAMILY: "Arial",sans-serif'><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Eris Lifesciences LimitedKRISHNAKUMAR VAIDYANATHANDirectorRemuneration45000000NA2065000020500002050000<DIV > <P class=MsoNormal style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 8pt; LINE-HEIGHT: 150%"><SPAN lang=EN-US style='FONT-FAMILY: "Arial",sans-serif; mso-ansi-language: EN-US'>The remuneration paid to the director is paid against the services provided by them to the company. The said remuneration is specifically approved by the shareholders in their AGM meeting held on 01<SUP>st</SUP> September, 2021 (which is a body superior to the Audit Committee). In any case, the financial results for the applicable quarter include the expenses pertaining to remuneration to this director and to this extent it gets approved by the Audit Committee while approving the financial results. </SPAN><SPAN style='FONT-FAMILY: "Arial",sans-serif'><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Eris Lifesciences LimitedSachin ShahChief Financial OfficerRemuneration12370000NA7170000610000610000<DIV > <DIV> <P class=MsoNormal style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 8pt; LINE-HEIGHT: 150%"><SPAN lang=EN-US style='FONT-FAMILY: "Arial",sans-serif; mso-ansi-language: EN-US'>The remuneration paid to the CFO is paid against the services provided by them to the company. The said remuneration is specifically approved by the Board of Directors vide circular resoution on 13-05-2022&nbsp;(which is a body superior to the Audit Committee). In any case, the financial results for the applicable quarter include the expenses pertaining to remuneration to the CFO and to this extent it gets approved by the Audit Committee while approving the financial results. </SPAN><SPAN style='FONT-FAMILY: "Arial",sans-serif'><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Lifesciences LimitedMilind TalegaonkarCompany SecretoryRemuneration3940000NA1820000220000240000<DIV > <DIV> <P class=MsoNormal style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 8pt; LINE-HEIGHT: 150%"><SPAN lang=EN-US style='FONT-FAMILY: "Arial",sans-serif; mso-ansi-language: EN-US'>The remuneration paid to the CS is paid against the services provided by them to the company. The said remuneration is specifically approved by the Board of Directors vide circular resoution on 13-05-2022&nbsp;(which is a body superior to the Audit Committee). In any case, the financial results for the applicable quarter include the expenses pertaining to remuneration to the CS and to this extent it gets approved by the Audit Committee while approving the financial results. </SPAN><SPAN style='FONT-FAMILY: "Arial",sans-serif'><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Lifesciences LimitedRAJEEV NAROTAM DALALIndependent directorRemuneration0NA173000000Eris Lifesciences LimitedVIJAYA SAMPATHIndependent directorRemuneration0NA180000003000000Eris Lifesciences LimitedKALPANA VASANTRAI UNADKATIndependent directorRemuneration0NA220000003500000Eris Lifesciences LimitedPRASHANT GUPTAIndependent directorRemuneration0NA180000002980000Eris Lifesciences LimitedParv BakshiRelative of KMPRemuneration350000NA, under omnibus approval280000030000Eris Lifesciences LimitedAMIT BAKSHIManaging DirectorAny other transactionReimbursement0NA18000000Eris Lifesciences LimitedINDERJEET SINGH NEGIDirectorAny other transactionReimbursement0NA18000000Eris Lifesciences LimitedKAUSHAL SHAHDirectorAny other transactionReimbursement0NA18000000Eris Lifesciences LimitedKRISHNAKUMAR VAIDYANATHANDirectorAny other transactionReimbursement0NA19000000Eris Lifesciences LimitedSachin ShahChief Financial OfficerAny other transactionReimbursement0NA18000000Eris Lifesciences LimitedMilind TalegaonkarCompany SecretoryAny other transactionReimbursement0NA18000000Eris Lifesciences LimitedTresna FoundationRelative of KMPAny other transactionCorporate Social Responsibility2100000NA, under omnibus approval210000000Eris Lifesciences LimitedEris Healthcare Private Limitedwholly owned SubsidiaryAny other transactionRoyalty Expense0Approved by Audit Committee on 29-07-2021 Audit committee has approved below mentioned criteria for Royalty amount For monthly net sales upto Rs. 9 Crores - Royalty to be 1% of monthly net sales For monthly net sales Rs. 9 Crores to Rs. 12 Crores - Royalty to be 3% of monthly net sales For monthly net sales above Rs. 12 Crores - Royalty to be 5% of monthly net sales85000000Eris Lifesciences LimitedAprica Healthcare Limited (Formerly known as UTH Healthcare Limited)wholly owned SubsidiaryAny other transactionRoyalty Expense0Approved by Audit Committee on 29-07-202119000000Eris Lifesciences LimitedAprica Healthcare Limited (Formerly known as UTH Healthcare Limited)wholly owned SubsidiaryAny other transactionRoyalty Expense0Approved by Audit Committee on 29-07-2021100000000Eris Lifesciences LimitedAprica Healthcare Limited (Formerly known as UTH Healthcare Limited)wholly owned SubsidiaryAny other transactionRoyalty Income0Approved by Audit Committee on 29-07-2021221000000Eris Lifesciences LimitedEris Healthcare Private Limitedwholly owned SubsidiaryAny other transactionRoyalty Income0Approved by Audit Committee on 29-07-2021228000000Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Healthcare Private LimitedGroup companyAny other transactionRoyalty Income0Approved by Audit Committee on 29-07-202125000000<DIV > <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Healthcare Private LimitedGroup companyAny other transactionRoyalty Income0Approved by Audit Committee on 29-07-202116000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Lifesciences LimitedEris Healthcare Private Limitedwholly owned SubsidiaryInterest received0NA1449000000Eris Lifesciences LimitedEris Therapeutics Limitedwholly owned SubsidiaryInterest received0NA557000000Eris Lifesciences LimitedEris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)SubsidiaryInterest received0NA25000000<DIV > <DIV> <DIV>At the time of execution of loan agreement the subsidiary was the wholly owned subsidiary and hence audit committee approval is not applicable</DIV></DIV></DIV>Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Healthcare Private LimitedGroup companyInterest received0NA156000000<DIV > <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned&nbsp;subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Therapeutics LimitedGroup companyInterest received0NA20000000Eris Healthcare Private LimitedERIS PHARMACEUTICALS PRIVATE LIMITEDSubsidiaryInterest received0NA1000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Healthcare Private LimitedEris Lifesciences LimitedHolding companySale of goods or services0NA2607000000<DIV > <DIV>transaction with a wholly owned subsidiary</DIV></DIV>Eris Healthcare Private LimitedAprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Group companySale of goods or services0NA000<DIV > <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Eris Healthcare Private LimitedEris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)Group companySale of goods or services0NA142000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Lifesciences LimitedAprica Healthcare Limited (Formerly known as UTH Healthcare Limited)wholly owned SubsidiarySale of goods or services0NA2641000000Eris Lifesciences LimitedEris Healthcare Private Limitedwholly owned SubsidiarySale of goods or services0NA4850000000Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Lifesciences LimitedHolding companySale of goods or services0NA000<DIV > <DIV>transaction with wholly owned subsidiary</DIV></DIV>Eris Lifesciences LimitedEris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)SubsidiaryAny other transactionComposit support service income0Approved by Audit Committee on 29-07-2021 Audit committee has approved below mentioned criteria for Royalty amount For monthly net sales upto Rs. 9 Crores - Royalty to be 1% of monthly net sales For monthly net sales Rs. 9 Crores to Rs. 12 Crores - Royalty to be 3% of monthly net sales For monthly net sales above Rs. 12 Crores - Royalty to be 5% of monthly net sales3000000Eris Lifesciences LimitedEris Healthcare Private Limitedwholly owned SubsidiaryAny other transactionComposit support service income0NA30000000Eris Lifesciences LimitedEris Therapeutics Limitedwholly owned SubsidiaryAny other transactionComposit support service income0NA6000000Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Group companySale of goods or services0NA380000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Lifesciences LimitedEris Therapeutics Limitedwholly owned SubsidiaryLoan0NA39350000000Loan0.08On demandUnsecuredFor businessEris Lifesciences LimitedEris Therapeutics Limitedwholly owned SubsidiaryLoan0NA39350000000Eris Lifesciences LimitedEris Healthcare Private Limitedwholly owned SubsidiaryLoan0NA5500000000Loan0.08On demandUnsecuredFor businessEris Lifesciences LimitedEris Healthcare Private Limitedwholly owned SubsidiaryLoan0NA15196000000Eris Lifesciences LimitedEris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)SubsidiaryLoan0NA4618000000Loan0.08On demandUnsecuredFor business<DIV > <DIV> <DIV>At the time of execution of loan agreement the subsidiary was the wholly owned subsidiary and hence audit committee approval is not applicable.</DIV></DIV></DIV>Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Therapeutics LimitedGroup companyLoan0NA000Loan0.08On demandUnsecuredFor business<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not require as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Therapeutics LimitedGroup companyLoan0NA1000000000<DIV > <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not required as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Healthcare Private LimitedGroup companyLoan0NA11000000000Loan0.08On demandUnsecuredFor business<DIV > <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not required as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Eris Lifesciences LimitedEris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)SubsidiaryAny other transactionTrade receivable0NA08200000Eris Lifesciences LimitedEris Therapeutics Limitedwholly owned SubsidiaryAny other transactionTrade receivable0NA0600000Eris Lifesciences LimitedAprica Healthcare Limited (Formerly known as UTH Healthcare Limited)wholly owned SubsidiaryAny other transactionTrade receivable0NA130000000Eris Lifesciences LimitedEris Healthcare Private Limitedwholly owned SubsidiaryAny other transactionTrade receivable0NA627000000Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)Group companyAny other transactionTrade receivable0NA8200008000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two subsidiary of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not required as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Healthcare Private LimitedGroup companyAny other transactionTrade receivable0NA53000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not required as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Healthcare Private LimitedEris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)Group companyAny other transactionTrade payable0NA53000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two subsidiaries of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not required as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Lifesciences LimitedAprica Healthcare Limited (Formerly known as UTH Healthcare Limited)wholly owned SubsidiaryAny other transactionTrade payable0NA175000000Eris Lifesciences LimitedEris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)SubsidiaryAny other transactionTrade payable0NA38000000Eris Lifesciences LimitedEris Healthcare Private Limitedwholly owned SubsidiaryAny other transactionTrade payable0NA175000000Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Healthcare Private LimitedGroup companyAny other transactionTrade payable0NA16000000<DIV > <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not required as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Eris Lifesciences LimitedEris Healthcare Private Limitedwholly owned SubsidiaryAny other transactionAdvances to creditor0NA033500000Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Lifesciences LimitedHolding companyAny other transactionAdvances to creditor0NA038100000<DIV > <DIV>transaction with wholly owned subsidiary</DIV></DIV>Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)Group companyAny other transactionOther current assets0NA090800000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two subsidiaries of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not required as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Lifesciences LimitedEris Healthcare Private Limitedwholly owned SubsidiaryLoan0NA3618100002648500000Eris Lifesciences LimitedEris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)SubsidiaryLoan0NA0464100000<DIV > <DIV> <DIV>At the time of execution of loan agreement the subsidiary was the wholly owned subsidiary and hence audit committee approval is not applicable.</DIV></DIV></DIV>Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Healthcare Private LimitedGroup companyLoan0NA207300001321400000<DIV > <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not required as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Therapeutics LimitedGroup companyLoan0NA1001000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not required as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Healthcare Private LimitedERIS PHARMACEUTICALS PRIVATE LIMITEDSubsidiaryLoan0NA1000001100000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two subsidiaries of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not required as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Eris Lifesciences LimitedAprica Healthcare Limited (Formerly known as UTH Healthcare Limited)wholly owned SubsidiaryAny other transactionPerpetual bond investment0NA2000000002000000000Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)Eris Healthcare Private LimitedGroup companyAny other transactionPerpetual bond investment0NA30000000300000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries of the Company and it is within the threshold limit of 10% of the annual consolidated turnover, hence the audit committee's prior approval is not required as per SEBI LODR Regulations. <?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>